# A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

> **NCT05432167** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 195 (actual)

## Conditions studied

- Uncontrolled Hypertension
- Chronic Kidney Diseases

## Interventions

- **DRUG:** CIN-107
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05432167
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-29
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432167, "A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05432167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*